

Index

- 2-D barcodes on medicine packs, 36
- 6 Rights of the Medication Use Process, 157
- absolute risk difference, 182
- Accountable Officer, role of, 141
- adherence to medication, lack of, 44, 86–7
- administration of medicines, 43
- actions following, 59
- additional information to check prior to, 57–8
- and adverse drug reactions, 68
- allergy status of patient, 49–50
- alternative therapies, 58
- authorization, 46–7
- checks to make prior to, 50–2
- definitions, 43–4
- delegation of, 53–4
- duty of care, 45
- errors in, 157
- homely medicines, 49
- medication errors, 45–6
- medicines exemptions, 48
- Patient Group Direction (PGD), 47–8
- Patient Specific Direction (PSD), 47
- preparing medication prior to, 54–7
- record keeping, 59
- reporting errors / incidents, 59–60
- self administration, 44–5
- self-purchased medications, 58–9
- staff safety, promoting, 60
- standards and policies, 46, 60–1
- up-to-date knowledge, 61
- adrenalin for anaphylactic reaction, 110
- adverse drug events (ADEs), 156
- adverse drug reactions (ADRs), 63
- in children, 165
- classification of, 64
- frequency of, 64–5
- groups of reactions/side effects, 70–3
- herbal medicines, 166
- link to prescribing errors in primary care, 9–10
- management of, 69–70
- MHRA definition of, 156
- in older patients, 43–4, 165
- prescribing factor, 15
- reporting via Yellow Card scheme, 69, 163–6
- risk factors for, 65–9
- timelines of, 65
- WHO definition of, 63
- age of patient and adverse drug reaction, 165
- link to medication incidents, 160
- prescribing factor, 12–3
- alcohol consumption, drug interactions, 76
- allergy to medications, dangers of, 68
- allergy status
- checking of, 32
- prior to medicine administration, 49–50
- prior to prescribing medication, 15
- and cross-sensitivities, 68
- NPSA recommendations on documentation of 169
- alternative therapies, 58
- amount of drug, units of, 117–8
- ampule solution, withdrawing into syringe, 54–5
- anaphylaxis after IV drug administration, 108–9
- treatment of, 109–10
- anticoagulants
- NPSA dispensing recommendations, 87
- risks contributing to ADRs, 86
- self-management of, 94
- antimuscarinic (anticholinergic) side effects, 71
- antiplatelet medicines
- aspirin and prevention of cardiovascular events, 187
- risk factors, 89
- antipsychotic drugs
- causing extrapyramidal symptoms, 72
- and neuroleptic malignant syndrome, 72
- appraisal system for prescribers, 19
- assembly of prescription, final dispensing checks, 32–6
- auditing, for evaluation of prescribing, 19
- automated dispensing, 36–7
- Bandolier website, evidence-based medicine, 177
- best practice, 60–1, 144
- NLH Search for guidance on, 179
- beta blockers, ADRs associated with, 72–3
- bias in research studies, checking for, 179–80
- bibliographical databases, 179
- black triangle drugs, ADR reporting, 164–5
- blinding, in clinical research trials, 180
- blood dyscrasias, agents causing, 73
- body surface area (BSA), calculating dose based on, 126–7
- brand versus generic names for drugs, safety issues 8
- breast feeding
- prescribing factor, 13
- and risk of ADRs, 68–9

Index

- British National Formulary (BNF), 79
- Building a Safer NHS for Patients: Improving Medication Safety* (Smith), 113, 144–5, 151
- calculations, 113–4
 - concentrations
 - amount per volume, 119–21
 - expressed as percentages, 121
 - expressed in ratios or parts, 121
 - safety tips, 122
 - test calculations and
 - answers, 122–3, 131–3
 - dosage, 123
 - based on body surface area (BSA), 126–7
 - based on body weight, 123–6
 - test calculations and
 - answers, 127, 133
 - dosage units, 114
 - prefixes, 115
 - safety tips, 118–9
 - test calculations and
 - answers, 119, 131
 - unit of amount, 117–8
 - units of mass, 116
 - units of volume, 115
 - rate of drug per unit time, 127–8
 - drops per minute, 128
 - milligrams per kilogram, 130
 - millilitres per hour, 128
 - test calculations and
 - answers, 130–1, 134–6
- carbamazepine, CYP P450 enzyme inducer, 75–6
- central venous catheters (CVCs), 99–100
- chemotherapy drugs, adverse reactions, 73
- children
 - greater likelihood of ADRs, 66
 - under-represented in clinical trials, 183–4
- cholinergic side effects, 71–2
- clinical check of prescription by pharmacist, 27–8
- clinical governance for safe prescribing, 7, 17–20
- clinical medication reviews, 91–3
- clinical trials *see* studies
- co-morbidities, issue for prescribers, 14
- Cochrane Reviews, 177
- cognitive function, prescribing factor, 14
- communication failures
 - during care transitions, 83
 - background to causes/ consequences, 83–6
 - medication safety
 - exemplars
 - antiplatelet medicines, 89
 - diuretics, 87–8
 - NSAIDs, 88–9
 - warfarin, 86–7
 - possible solutions, 89–90
 - medicines reviews, 91–3
 - proactive monitoring, 90–1
 - strengthening patient knowledge, 93–4
- communication and team-working, prescribing safety, 7, 20–1
- community pharmacists
 - NPSA advice on dispensing
 - anticoagulants, 87
 - prescribing safety issues, 21
 - reluctance to challenge prescriptions, 85
- competencies
 - definition of, 53
 - improvement of, 167
- computer generated
 - prescriptions, benefits of, 21
- computerized decision support systems (CDSS), 7, 21
- computerized physician order entry (CPOE), 21, 37–8
- concentration of dose, calculation of, 119–22
- concordance with medication, 44
- confidence intervals (CIs), 183
- confounding factors in studies, 180
- consent for treatment, 14, 51
- continuing professional development (CPD) for prescribers, 19
- controlled drugs (CDs), 139
- good practice in
 - management of, 144
- guidelines for
 - administration of, 52
- Healthcare Commission's 2007 report, 144
- legislation, 139
- prescribing and supply of
 - by medical practitioners, 142
 - by non-medical practitioners, 142–4
 - second signature requirement, 52
 - Shipman Inquiry, 27, 142
 - see also* opioid medicines
- cross-sensitivities, 68
- cytochrome P450 databases, 80
- cytochrome P450 enzymes
 - and drug interactions, 75–7
- Database of Abstracts of Reviews of Effectiveness (DARE), 177
- Database of Uncertainties about the Effects of Treatments, 188
- decision-making
 - about treatment, 187–8
 - general practice versus hospital, 11–2
 - using technology to support, 21
- deductive reasoning
 - approach to prescribing, 11
- delegation of medicine administration, 53–4
- diamorphine and morphine, NPSA safety alert, 146
- dietary supplements,
 - interaction with medication, 77
- discretionary medicines,
 - administration of, 49
- dispensing accuracy check, 28–9
- dispensing errors, 157

- final dispensing check, 32–3
- error detection and checking routines, 35–6
- harm caused by, 33
- perceived causes of, 34–5
- product verification systems, 36
- dispensing safety, 25
 - education/training issues, 38–9
 - impact of new technologies, 36–8
 - prescription assembly, evidence for final dispensing check, 32–6
 - prescription management process, 26–9
 - prescription screening, evidence for effectiveness of, 30–2
 - prescription types, 25–6
- disposal of medication, 60
- diuretics, electrolyte disturbance, 87–8
- dosage calculations, 123
 - based on body surface area (BSA), 126–7
 - based on body weight, 123–6
- dosing errors, NPSA recommendations for minimizing, 168
- drug calculations *see* calculations
- drug dictionaries, 17
- drug extravasation, 107
- drug identification, NPSA recommendations, 168–9
- drug interactions, 73
 - alerts, GPs and pharmacists overriding, 85
 - distribution interactions, 74–5
 - excretion interactions, 77–8
 - identifying potentially harmful, 78
 - information sources, 79–80
 - management of, 78
 - metabolism interactions, 75–7
 - pharmacodynamic, 74
 - pharmacokinetic, 74
 - prescribing factor, 13–4
 - drug omissions, NPSA recommendations, 168
 - drug verification, dispensing check, 36
 - duty of care, 45
 - DynaMed, clinical reference tool, 177
 - e-learning competencies, 167
 - elderly people
 - higher likelihood of ADRs, 65–6
 - under-represented in clinical trials, 184
 - electronic prescribing (EP), benefits of, 21, 37–8
 - electronic transmission of prescriptions (ETP), 38
 - epidural analgesia, NPSA safety alert, 146–8
 - error detection and checking routines, dispensing, 35–6
 - Essential Drugs Programme* (WHO), 8
 - ethnicity
 - prescribing factor, 13
 - and risk of ADRs, 66
 - evidence-based medicine, 173, 189
 - applying to clinical expertise, 185–7
 - future support for, 189
 - learning from errors/incidents, 188
 - National Library for Health (NLH), 179
 - patient values, 187–8
 - research evidence
 - cautious approach with new, 185
 - classification of, 174–5
 - determining the best, 175–6
 - limitation of, 183–5
 - sourcing the best, 176–7
 - steps involved in, 173
 - studies
 - checking for bias in, 179–80
 - checking if result is due to chance, 183
 - reporting of results from, 180–3
 - searching for, 178–9
 - Expert Patient Programme, UK, 93
 - extrapyramidal symptoms, antipsychotic drugs causing, 72
 - extravasation of IV drug, 107
 - female gender
 - and great number of ADRs, 67
 - prescribing factor, 13
 - see also* pregnancy
 - generic substitution, safety issues, 8, 151–2
 - genetic variations and ADRs, 66–7
 - grapefruit juice, interaction with medicines, 76
 - guidance
 - on prescription of CDs, 141–2
 - sources of, 177, 179
 - see also* National Patient Safety Agency (NPSA)
 - guidelines
 - for administration of CDs, 52
 - for infection control, 60
 - preparation of IV medication prior to administration, 54–7
 - for safe prescribing, 18
 - Health Technology Assessment Database (HTA), 177
 - herbal preparations, interaction with medication, 77
 - heuristic basis for prescribing, 11–2
 - high risk medication practices
 - calculating rate of drug administration, 127–30
 - NPSA recommendations, 167
 - homely medicines, 49
 - hospital admissions
 - drugs mostly responsible for, 86–9
 - due to ADRs, 63, 70, 162

Index

- hospital admissions (*cont.*)
 - preventable drug-related, 43–4, 84–5
 - due to inadequate communication, 85
 - extent of the problem, 158
- independent prescribing, 2, 142–4
- information for patients
 - about medicines, sources of, 44, 93
- Information Prescriptions, 93
- information processing, Miller’s number, 16–7
- information retrieval (IR), computerized prescriptions improving, 21
- information sharing
 - among professionals, 19–20
 - prescribing of controlled drugs, 141–2
 - and team-working, 19–20
- information technology
 - for dispensing, 36–8
 - patient use of social media, 93
 - for prescribing, 21
 - strengthening patient information, 94
- informed consent, 11, 14, 50–1
- infusion solution, adding a medication to, 56–7
- infusion systems, 100
- syringe pumps, 100
- volumetric pumps, 101
- interventions, balancing risk of harm with benefits, 186–7
- intramuscular (IM) drug administration, 101–2
- intravenous (IV) drug administration, 99–100
- error rate for, 157
- preparation guidelines, 54
- kidney dysfunction
 - and adverse drug reactions, 67
 - drugs interaction with excretion, 77–8
 - prescribing factor, 13
- Know Your Numbers (KYN) concept, 94
- labelling of medicines, 28–9
 - dispensing errors, 33
 - injectable medicines/infusion containers, 57
- legislation
 - allowing non-medical prescribers, 2
 - on controlled drugs, 139–41
 - following Shipman Inquiry, 141
 - medicines exemptions, 48
 - Patient Group Directions, 47–8
 - seriousness of breaching, 46
- lifelong learning for prescribers, 19
- lifestyle
 - changing as alternatives to drugs, 10
 - influence on medication safety, 36
- liver dysfunction
 - flucloxacillin induced, 65
 - increasing adverse drug reactions, 67
 - prescribing factor, 13
- mass, units of, 116–7
- MedCheck system, 94
- medical records, 20
 - accessibility problems, 85
 - sharing of, 20
- medication checks prior to administration, 51–2
- Medication Process, errors within, 156–8
- medication safety
 - NPSAs 7 key actions to improve, 3, 166–70
 - schemes and initiatives to improve, 4
- medication safety incidents, 1, 45–6, 155
 - improving reporting of, 166–70
 - NRLS data, 158–61
 - terms and definitions, 155–6
 - within the Medication Process, 156–8
 - see also* reporting medication errors
- medicinal products
 - definitions of, 43
 - types of, 43
- medicine regimens, patient-doctor discordance, 86–7
- medicines exemptions, 48
- Medicines and Healthcare Products Regulatory Agency (MHRA), 163
- medicines information departments, advisory capacity, 80
- medicines management, 43–4
- medicines reconciliation, 85
- medicines reviews, 91–3
- Medicines Use Review (MUR), 91
- MEDLINE library, 178
- mentorship for prescribers, 19
- midazolam injections, reducing overdose risk, 149
- Miller’s number, information processing, 16–7
- Misuse of Drugs Act (1971), 139
- Misuse of Drugs Regulations (2001), controlled drugs, 140–1
- monitoring of medication outcome, errors in, 158
- monitoring of treatment, 90–1
- morphine and diamorphine, NPSA safety alert, 146
- multiple drug use and ADRs, 67
- National Library for Health (NLH), 179
- National Patient Safety Agency (NPSA)
 - anticoagulant recommendations for pharmacists, 87
 - definition of medication safety incident, 1
 - five key changes to strengthen reporting and learning, 170
 - incidents associated with injectable medicines, 98
 - medication errors, 45–6
 - patient identification methods, 50
 - Patient Safety Alerts
 - seven key actions to improve medication safety, 3, 166

Index

- diamorphine and morphine, 146
- epidural injections and infusions, 146–8
- Rapid Response Reports dosing errors with opioid medicines, 148–9
- overdose with midazolam injections, 149
- National Reporting and Learning System (NRLS), 1, 155, 188
 - characteristics of data collected, 158–9
 - controlled drugs, alerts issued, 146–9
 - findings from 2007 data (England and Wales), 159–60
 - lack of non-medical prescriber errors, 9
 - prescription screening problems, 30, 32
- near misses, 25
 - during prescription assembly, 33
 - under-reporting of, 155
- needle stick injury, risks of, 107
- neonatal prescribing errors, 9
- neuroleptic malignant syndrome, 72
- NHS Clinical Knowledge Summaries service (CKS), 177
- NHS Economic Evaluation Database (NHS EED), 177
- NICE guidance on health promotion, 177
- NICE research and development programme, 188
- NIHR Health Technology Programme, 177
- non-medical prescribers, 2, 9
 - controlled drugs prescribing, 3, 142–4
 - Patient Group Directions (PGDs), 2–3
 - training for, 2
- non-steroidal anti-inflammatory drugs (NSAIDs)
 - ADRs caused by, 73, 88
- public awareness and alternatives to, 88–9
- numbers needed to harm (NNH), 183
- numbers needed to treat (NNT), 182
- Nurse Independent Prescribers (NIPs), 2
 - controlled drugs available for, 143
 - errors in prescribing, 3
 - prescription of controlled drugs, 3
 - training for, 2
- Nursing and Midwifery Council (NMC),
 - regulations for medicine administration, 46
- odds, odds ratio and relative risk, 181–2
- older people *see* elderly people
- omission of medicines, NPSA recommendations, 168
- opioid medicines, 139
 - adverse side effects of, 72
 - brand or generic names, safety issues, 151–2
 - in cancer pain and palliative care, 149–50
 - medication incidents, 139
 - NPSA rapid response report on dosing errors, 148–9
 - NPSA safety alerts, 146–8
 - in persistent non-cancer pain, 150–51
 - recommendations for use of, 145
- optometrist prescribers, 2
- oral contraception
 - prescribing factor, 13
 - and risk of deep vein thrombosis, 184
- Our health, our care, our say* (DH white paper), 93
- outcome measures for safe prescribing, 18–9
- P-values, results of clinical trials, 183
- palliative care, use of opioids in, 149–50
- panic attacks, confusion with anaphylactic reaction, 108–9
- parallel imports, 8
- parenteral drug administration, 97
- incidents reported to NPSA, 98
- methods of, 98–9
- infusion systems, 100–1
- intramuscular (IM) drug administration, 101–2
- intravenous drug administration, 99–100
- subcutaneous (SC) drug administration, 102
- practicalities of flushing between drugs and venous catheter locks, 106–7
- preparing and checking drugs, 102–6
- prescriptions, 102
- reasons for, 97–8
- reporting drug errors/ adverse events, 110
- specific hazards of anaphylaxis, 108–9
 - treatment of, 109–10
- drug extravasation, 107
- needle stick injury to staff, 107
- patient condition,
 - checking prior to drug administration, 52
- patient decision aids, 187–8
- Patient Group Directions (PGDs), 2–3, 47–8, 53, 143–4
- patient identification, 47, 50–1
- NPSA recommendations, 168–9
- patient information leaflets (PILs), 93
- Patient Specific Direction (PSD), 47
- penicillin
 - allergy, complications of, 68
 - and probenecid, 78
- peripheral venous cannulae, 99

Cambridge University Press

978-0-521-72163-9 - Medication Safety: An Essential Guide

Edited by Molly Courtenay and Matt Griffiths

Index

[More information](#)

Index

- peripherally inserted central cannulae (PICCs), 100
- personal development plan (PDP), prescribers, 19
- pharmacies, community and hospital, 26
- pharmacists
 - anticoagulant recommendations, 87
 - calculation skills training, 113
 - and Medicines Use Reviews (MURs), 91
 - monitoring patients taking diuretics, 88
 - prescribing safety issues, 20–1
 - queries from to prescribers, 84
 - reluctance to challenge problems in prescriptions, 85, 91
 - as supplementary prescribers, 2
 - see also* dispensing safety
- pharmacy supply chain issues, 8
- PICO method for formulating questions, 178
- placebo effect, 180, 181–2
- point of care prescribing, key issues
 - access to up-to-date prescribing information, 16–7
 - decision-making approaches, 11–2
 - is prescribing the right decision? 10–1
 - issuing a safe prescription, 12–5
 - knowing what to do if things go wrong, 15–6
 - patient follow-up, 15
 - review and 'safety netting', 15
- pregnancy
 - lack of research evidence for drugs, 184
 - prescribing factor, 13
 - and risk of ADRs, 68
- preparation of medication prior to administration, 54–7
- prescriber pressures and tensions, 20
- prescribing errors, 156–7
 - detected by pharmacist during routine screening, 30–2
 - neonatal, 9
 - and prescription cancellations, 9
 - in primary care, 9–10
 - taxonomies for, 18
 - US reports, 8–9
- prescribing information, access to, 16–7
- prescribing safety, 7–8
 - communication and team-working, 20–1
 - importance of, 8–10
 - IT systems support, 21
 - key issues at point of care, 10–7
 - systems to ensure, 17–9
- prescription
 - cancellations, link to prescribing errors, 9
 - of parenteral drugs, 102
 - screening, evidence for effectiveness, 30
 - types and care settings, 25–6
- prescription management
 - process, 26
 - clinical check, 27–8
 - dispensing accuracy check, 28–9
 - receipt and validity check, 26–7
- primary care
 - prescribing errors in, 9–10
 - under-reporting of medication incidents, 3–4, 159
 - use of heuristics for prescribing decisions, 11–2
- processes for safe prescribing, 18
- protein binding, drug interactions, 74–5
- publication bias, 176, 183
- radio-frequency ID microchips on medicine packs, 36
- randomization in research studies, 180
- rashes, adverse drug reaction, 71
- rational basis for prescribing, 11
- receipt and validity check of prescriptions, 26–7
- reconstituting powder in vial and drawing solution into syringe, 55–6
- record keeping, medication administration, 59
- relative risk and odds ratio, 181–2
- reporting medication errors, 59–60, 110
 - NPSA recommendations for increasing, 167
- patient safety incidents, 161–2
 - see also* National Reporting and Learning System (NRLS)
- research evidence
 - cautious approach with new, 185
 - classification of, 174–5
 - determining which is the best, 175–6
 - limitation of available, 183–5
 - sourcing the best, 176–7
- revalidation system, prescribers, 19
- risks of medication, 181–2
 - balancing harm with benefits, 186–7
- robotic dispensing, 36–7
- routine screening of prescriptions, evidence for effectiveness, 30
- sample size of clinical trials, effect on results, 180, 184–5
- Scotland, medication safety initiatives, 160–1
- Scottish Intercollegiate Guideline Network, 177
- screening of prescriptions, evidence for effectiveness, 30
- 'second checking' and dispensing errors, 36
- second signature for CD administration, 52
- secondary care controlled drugs

- good practice, 144
- guidelines for, 52
- second signature requirement, 52
- dispensing errors, 33, 34–6
- electronic prescribing, 37
- medicines information departments, 80
- prescribing decisions, 11–2
- prescription handling, 26, 27–8, 29
- self-administration, 44–5
 - see also* hospital admissions
- selective publishing, 183
- self administration of medication, 44–5
- self management training, 93–4
- self-purchased medications, 58–9
- serotonin syndrome, agents causing, 72
- Shipman Inquiry, 27, 141–2
- side effects of medicines, 63–4
- skin changes, anaphylactic reactions, 108
- skin rashes, adverse drug reaction, 71
- staff safety, promoting, 60
- staff skills, improving, 167
- staff training, pharmacists, 38–9
- standards and local policies, 46, 60–1, 158
- Stockley's Drug Interactions, 8th Edition* (Baxter), 80
- structures for safe prescribing, 18
- studies
 - continuous and dichotomous data, 180–3
 - evaluating bias in results, 179–80
 - P-value and confidence intervals, 183
 - searching for evidence-based, 178–9
 - sub-group analysis, 180
 - subcutaneous (SC) drug administration, 102
 - summaries of evidence, sources of, 177
 - Summary of Product Characteristics (SPCs), 49, 58, 64–5, 68, 79
 - supplementary prescribing, 2, 3, 142
 - supply chain issues, pharmacy, 8
 - synopses of evidence, sources of, 177
 - syntheses of research evidence, sources of, 177
 - syringe pumps, 100
 - systems for safe prescribing, 18–9
 - tablets, administration of, 54
 - taxonomy for reporting prescribing safety issues, 18–9
 - team-working, for safety in prescribing, 19–21
 - thalidomide, 69, 162–3
 - time constraints, processing information prior to prescribing, 16–7
 - training
 - in calculation skills, 113–4
 - to deal with emergencies, 15–6
 - lifelong learning for prescribers, 19–20
 - for non-medical prescribers, 2
 - NPSA work-based competences, 167
 - of patients in self-management, 93–4
 - of pharmacists, 38–9
 - two-dimensional barcodes on medicine packs, 36
 - uncertainty about treatment effects, 188
 - urea and electrolytes (U&Es), monitoring of, 87–8
 - validity checking of prescriptions, 26–7
 - vascular access devices (VADs), 99–100
 - venous catheters, flushing between drugs and venous catheter locks, 106–7
 - vial solution/suspension, withdrawing into syringe, 55
 - vicarious liability, 51, 58, 60
 - volume, units of, 115
 - volumetric pumps, 101
 - warfarin, safety issues, 76, 86–7
 - weight of patient
 - calculating dose based on, 123–6
 - prescribing factor, 12–3
 - weight, units of, 116–7
 - Yellow Card scheme for ADRs, 69, 188
 - limitations of data obtained from, 79–80
 - using to report ADRs, 163–6